651 results on '"Harada-Shiba, Mariko"'
Search Results
102. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
103. Abstract 12027: Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia Who Participated in Sequential Studies of Alirocumab and Evinacumab
104. Current concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor
105. Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel
106. Current Diagnosis and Management of Abetalipoproteinemia
107. CD36 Expression in Human Monocytic Leukemia Cell Lines: THP-1 and THP-1 Subtype, Show Different Expressions of Type I and Type II Scavenger Receptors
108. Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments
109. Current Diagnosis and Management of Primary Chylomicronemia
110. Current Diagnosis and Management of Tangier Disease
111. Diagnosis and Management of Sitosterolemia 2021
112. Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia
113. Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
114. Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant
115. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
116. Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
117. How Can We Improve the Diagnosis Rate of Familial Hypercholesterolemia by Amending Diagnosis Criteria?
118. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma
119. Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
120. A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency
121. Effects of Dietary Cholesterol on Tissue Ceramides and Oxidation Products of Apolipoprotein B-100 in ApoE-Deficient Mice
122. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial
123. Association of ceramides in human plasma with risk factors of atherosclerosis
124. Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia
125. Inhibition of Tumor Growth and Metastasis by a Combination of Anti-VEGF-C and Enhanced IL-12 Therapy in an Immunocompetent Mouse Mammary Cancer Model
126. Current concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor.
127. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy
128. Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia
129. Abstract 207: A Catalogue of the Pathogenic Mutations of LDL Receptor Gene in Japanese Familial Hypercholesterolemia
130. Safety, Tolerability, and Pharmacokinetics of Evinacumab, an Angiopoietin-Like Protein 3 Inhibitor, in Healthy Japanese and Caucasian Subjects†
131. Morphological Characteristics of Aortic Stenosis in Familial Hypercholesterolemia and Non-Familial Hypercholesterolemia in the Elderly
132. Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin
133. What Arteries are Affected in Familial Hypercholesterolemia?
134. Effect of modular conjugation strategy forN-acetylgalactosamine-targeted antisense oligonucleotides
135. Autosomal Recessive Hypercholesterolemia Long-Term Cardiovascular Outcomes
136. Multimodality assessment of left ventricular dysfunction in Takayasu arteritis and familial hypercholesterolaemia
137. LONG TERM EFFECT OF LDL-APHERESIS IN HOMOZYGOUS and HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: SY7–4
138. Clinical Features and Genetic Analysis of Autosomal Recessive Hypercholesterolemia
139. Effective gene silencing activity of prodrug-type 2′-O-methyldithiomethyl siRNA compared with non-prodrug-type 2′-O-methyl siRNA
140. Apheresis Technology for Prevention and Regression of Atherosclerosis
141. Rebound Curve Following LDL-Apheresis Reflects Catabolic Rate of Plasma Cholesterol And The Synthetic Rate of Lp(A)
142. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy.
143. Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBP[small beta, Greek] gene
144. Synthesis of MonovalentN‐Acetylgalactosamine Phosphoramidite for Liver‐Targeting Oligonucleotides
145. Familial Hypercholesterolemia and Lipoprotein Apheresis
146. No enhancing effects of plasmid-specific histone acetyltransferase recruitment system on transgene expression in vivo
147. Remembrance of Dr Akira Yamamoto
148. Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study
149. Crude α-Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism
150. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.